ATLANTA, GEORGIA, USA: New American Cancer Society recommendations introduce regular PSA testing for men aged 50 to 69, with earlier and more frequent screening for those at higher risk.
The American Cancer Society (ACS) has updated its prostate cancer screening guidelines for the first time since 2010. It now recommends a prostate-specific antigen (PSA) blood test every two years for men at average risk aged 50 to 69.
Men at higher risk should begin screening earlier, with some advised to undergo annual testing from age 45. The updated guidance also introduces clearer steps for evaluating elevated PSA results and reducing unnecessary biopsies and treatment.
What Has Changed in the 2026 Prostate Cancer Screening Guidelines?
The American Cancer Society has moved from a largely discussion-based approach to a more direct recommendation for regular prostate cancer screening.
Under its previous guidance, the organization encouraged men to discuss the benefits and risks of PSA testing with their healthcare providers. It did not recommend a specific routine screening schedule for average-risk men.
The new guidance introduces defined screening intervals based on age and individual risk.
The ACS says stronger evidence now shows that PSA-based screening can reduce prostate cancer deaths and lower the risk of diagnosis at an advanced stage. Advances in MRI, biomarker testing and active surveillance have also made it easier to manage abnormal results without immediately proceeding to invasive procedures.
The updated guideline was published on November 12, 2026, in CA: A Cancer Journal for Clinicians. It followed a systematic review of available evidence and a modelling study commissioned by the ACS to assess the benefits and potential harms of different screening strategies.
The changes were also covered in a Daily Mail report on the updated prostate cancer screening recommendations.
The main objective is to identify potentially aggressive cancers earlier while reducing unnecessary investigations and treatment for slow-growing cancers. Source: (Hoffman et al. 2026)
Who Should Get Screened for Prostate Cancer?
The updated guidelines divide men into different groups according to their age and risk of developing prostate cancer.
The recommended screening frequency differs between average-risk men and those with a family history or other recognized risk factors.
1. Average-Risk Men Aged 50 to 69
The ACS recommends a PSA blood test every two years for men at average risk between the ages of 50 and 69.
This applies to men who do not fall into the higher-risk categories identified in the guideline.
Before starting screening, men should understand the potential benefits, limitations and possible harms of PSA testing.
Regular testing can help identify changes in PSA levels and detect cancers that may require further investigation.
2. Black Men and Men With a Strong Family History
Men with a higher risk of prostate cancer should begin screening earlier.
The ACS recommends annual PSA testing from age 45 through age 69 for:
- Black men.
- Non-Black men with one first-degree relative, such as a father, brother or son, diagnosed with prostate cancer before age 65.
- Non-Black men with multiple first-degree relatives diagnosed with prostate cancer, regardless of their age at diagnosis.
These recommendations reflect the higher incidence and mortality associated with prostate cancer in certain populations and the increased risk associated with a strong family history.
3. Men With One Family Member Diagnosed at Age 65 or Older
Non-Black men with one first-degree relative diagnosed with prostate cancer at age 65 or older should also begin screening at age 45.
However, the recommended frequency is different from that for men with a stronger family history.
The ACS recommends PSA testing every two years from ages 45 to 69 for this group.
4. Men Aged 70 to 74
For men aged 70 to 74, the benefits of continued screening are less certain.
The ACS recommends an individual discussion with a healthcare provider before deciding whether to continue PSA testing.
Overall health, life expectancy, previous PSA results and personal preferences should influence the decision.
Men in this age group who choose to continue screening should undergo testing every two years.
5. Men Aged 75 and Older
Routine screening is not recommended for men aged 75 and older.
However, some exceptionally healthy men aged 75 to 79 may discuss continued screening with their healthcare provider, particularly when previous PSA results show rising levels.
Screening is discouraged after age 80.
The ACS also advises against screening at any age for men in poor health who are not expected to live for at least another 10 years. The potential benefits of detecting a slow-growing cancer may be limited in these circumstances. (American Cancer Society 2026)
Prostate Cancer Screening Guidelines at a Glance
The following table summarises the updated ACS recommendations.
| Age and risk group | Recommended PSA screening |
|---|---|
| Average-risk men aged 50-69 | Every 2 years |
| Black men aged 45-69 | Every year |
| Non-Black men with a strong family history, aged 45–69 | Every year |
| Non-Black men with one relative diagnosed at 65 or older, aged 45-69 | Every 2 years |
| Men aged 70-74 | Individual decision; every 2 years if continuing |
| Men aged 75-79 | Not routinely recommended; selected healthy men may discuss continuation |
| Men aged 80 and older | Screening discouraged |
Men with inherited genetic conditions associated with prostate cancer risk should also discuss their screening needs with a healthcare provider. The ACS specifically identifies BRCA2 mutations as an important risk factor.
These recommendations are intended to guide clinical decisions. They do not mean that every man in a particular age group must undergo testing without discussing its benefits and limitations.
Why Are Prostate Cancer Screening Guidelines Changing?
The guideline update comes amid a rise in prostate cancer diagnoses in the United States, including an increase in advanced-stage cases.
According to the American Cancer Society’s 2026 cancer statistics:
- 333,830 new prostate cancer cases are expected in the United States during 2026.
- 36,320 deaths from prostate cancer are expected during the same year.
- Prostate cancer diagnoses increased by approximately 3% annually between 2014 and 2022.
The steepest increase occurred in advanced-stage diagnoses, which is a major concern for cancer specialists.
The ACS attributes much of the overall increase in diagnoses to more men undergoing screening. However, advanced-stage cases are also rising, suggesting that many potentially serious cancers are still being detected too late.
The organization believes that a more structured screening approach could help identify aggressive cancers earlier and reduce the number of men diagnosed after the disease has spread. (American Cancer Society, 2026)
Why Black Men Face a Higher Risk
The updated guidelines place particular emphasis on screening Black men earlier.
According to the ACS, Black men in the United States are 67% more likely to be diagnosed with prostate cancer than White men. They also have nearly twice the prostate cancer mortality rate.
Black men are more likely to develop aggressive forms of the disease and receive a diagnosis at a younger age.
Family history is another important factor. Men with a father, brother or son diagnosed with prostate cancer, particularly before age 65, may have a greater risk of developing the disease.
These differences explain why the ACS recommends annual PSA testing from age 45 for certain higher-risk groups rather than waiting until age 50. (American Cancer Society, 2026)
What Is a PSA Test and How Does It Detect Prostate Cancer?
A prostate-specific antigen (PSA) test is a blood test used to assess the possibility of prostate cancer.
PSA is a protein produced by cells in the prostate gland. The test measures the amount of this protein in the blood.
Higher PSA levels can indicate an increased risk of prostate cancer and may lead to further investigations.
However, a PSA test cannot confirm whether a man has cancer. An elevated result does not automatically mean that cancer is present or that a biopsy is necessary.
The test is used as an initial screening tool to identify men who may benefit from additional assessment.
What PSA Level Is Considered High?
The updated ACS recommendations identify the following PSA levels as elevated:
| Age group | Elevated PSA level |
|---|---|
| Men aged 45 to 69 | 3.0 ng/mL or higher |
| Men aged 70 to 74 | 6.5 ng/mL or higher |
These thresholds help identify men who may require further testing.
They should not be interpreted as definitive cancer diagnostic values. A healthcare provider must consider the patient’s age, medical history, previous PSA results and other clinical findings. (American Cancer Society, 2026)
What Happens When PSA Levels Are Elevated?
The updated recommendations introduce a more structured process for evaluating elevated PSA results.
Instead of immediately proceeding to a biopsy, the ACS recommends repeating the PSA test to confirm the result.
The repeat test should preferably take place between two weeks and three months after the initial elevated result.
If the PSA level remains elevated, most men should undergo additional assessment.
This may include:
Prostate MRI: Magnetic resonance imaging helps identify suspicious areas within the prostate. It provides information that can guide decisions about whether a biopsy is necessary.
Biomarker testing: Additional laboratory tests can help assess the likelihood of clinically significant prostate cancer and support decisions about further investigation.
Prostate biopsy: A biopsy involves collecting small tissue samples from the prostate for examination under a microscope. It is required to confirm a prostate cancer diagnosis.
For men with a very high PSA level or strong clinical suspicion of cancer, a healthcare provider may recommend proceeding directly to a biopsy.
The purpose of this approach is to reduce unnecessary biopsies while ensuring that men with potentially aggressive cancer receive appropriate evaluation.
Is a Digital Rectal Examination Still Recommended?
A digital rectal examination (DRE) involves a healthcare professional inserting a gloved finger into the rectum to examine the prostate gland.
Although this examination has traditionally been used in prostate assessments, the updated ACS guidance does not recommend DRE as a routine prostate cancer screening test.
However, a doctor may still use it during a diagnostic evaluation when there is a concern about prostate cancer, such as an elevated PSA result.
The current screening recommendation focuses on PSA-based blood testing.
What Are the Risks of Prostate Cancer Screening?
Although PSA testing can help detect prostate cancer earlier, it also has limitations.
The ACS emphasizes that screening decisions should consider both the potential benefits and possible harms.
Some of the main concerns include:
False-Positive PSA Results
A false-positive result occurs when PSA levels are elevated even though the man does not have prostate cancer.
This can lead to additional blood tests, imaging procedures and biopsies.
Repeating an elevated PSA test before proceeding to further investigations can help reduce unnecessary procedures.
Unnecessary Prostate Biopsies
A biopsy can provide important diagnostic information, but it is an invasive procedure.
Possible complications include bleeding and infection.
Using repeat PSA testing, MRI and biomarker tests can help doctors identify men who are more likely to benefit from a biopsy.
Overdiagnosis and Overtreatment
Some prostate cancers grow very slowly and may never cause symptoms or affect a man’s health during his lifetime.
Detecting these cancers can lead to overdiagnosis. Treatment of cancers that would not have caused significant problems is known as overtreatment.
Prostate cancer treatment can cause side effects, including:
- Urinary incontinence.
- Erectile dysfunction.
- Bowel problems.
These complications may affect a patient’s quality of life and can sometimes be long-lasting.
The updated guidelines aim to reduce these risks by encouraging better risk assessment and appropriate management after screening. (American Cancer Society, 2026)
Why Active Surveillance Is Important for Low-Risk Prostate Cancer
Another important part of the updated guidance is the recommendation to offer active surveillance as the initial management approach for men diagnosed with low-risk prostate cancer.
Not every prostate cancer grows quickly or spreads to other parts of the body. Some cancers remain slow-growing and may not require immediate treatment.
Active surveillance involves monitoring the cancer through regular PSA tests, MRI scans and follow-up biopsies when needed.
Doctors assess whether the cancer shows signs of becoming more aggressive. Treatment may be recommended if the risk changes.
This approach can help suitable patients avoid or delay complications associated with surgery or radiation therapy.
Active surveillance does not mean ignoring cancer. It involves regular medical monitoring and a treatment plan when further intervention becomes necessary. (Hoffman et al. 2026)
Why Early Detection Matters in Prostate Cancer
Early-stage prostate cancer often develops without noticeable symptoms. This means some men may have the disease without experiencing any changes in their health.
Detecting the cancer before it spreads can improve treatment options and survival outcomes.
According to the American Cancer Society, the five-year relative survival rate for prostate cancer is:
- More than 99% when the cancer is diagnosed before spreading beyond the prostate or after spreading only to nearby tissues.
- 38% when the cancer has spread to distant parts of the body.
These figures demonstrate the difference in outcomes associated with the stage at diagnosis. However, they are population-level estimates and cannot predict an individual patient’s outcome.
They also do not mean that screening alone guarantees a better outcome. Cancer type, aggressiveness, overall health and treatment response remain important factors. (American Cancer Society, 2026)
What Are the Warning Signs of Prostate Cancer?
Early prostate cancer often has no noticeable symptoms. This is one reason screening may be considered for men who have an increased risk.
As the disease progresses, some men may experience:
- Difficulty starting or maintaining urine flow.
- A weak or interrupted urine stream.
- Frequent urination, particularly at night.
- Blood in the urine or semen.
- Bone pain if the cancer has spread to the bones.
These symptoms do not automatically indicate prostate cancer. They can also occur with other prostate or urinary conditions.
Men experiencing persistent urinary changes, blood in their urine or semen, or unexplained bone pain should seek medical assessment.
Screening and diagnostic testing serve different purposes. Screening aims to identify possible disease before symptoms appear, while diagnostic testing investigates symptoms or abnormal findings. (American Cancer Society, 2026)
Do the New Prostate Cancer Screening Guidelines Apply to Men in India?
The latest ACS recommendations are intended for clinical practice in the United States. They should not automatically be treated as universal screening guidelines.
India has a different healthcare context, and its clinical recommendations do not currently support routine population-based PSA screening.
The Indian Council of Medical Research (ICMR), in its 2023 Consensus Document for Management of Prostate Cancer, states that population-based prostate cancer screening cannot be recommended for the Indian population at any age.
The document explains that available evidence had not demonstrated an improvement in prostate cancer-specific survival or overall survival through routine population-based screening.
This distinction is important.
Population-based screening involves routinely testing an entire group of people who do not have symptoms. It is different from individual clinical evaluation when a man has symptoms, relevant medical history or an elevated risk.
The ICMR document supports PSA testing as part of the evaluation when prostate cancer is clinically suspected.
Indian men should therefore discuss their individual risk and screening needs with a urologist rather than automatically follow the US testing schedule. (Indian Council of Medical Research, 2023)
What Men Should Know About the Updated Screening Recommendations
The American Cancer Society’s 2026 update marks a significant change in its approach to prostate cancer screening.
Average-risk men aged 50 to 69 are now advised to undergo PSA testing every two years. Men at higher risk, including Black men and those with certain family histories, should begin screening at age 45, with annual testing recommended for specific groups.
The new guidance also places greater emphasis on repeat PSA testing, prostate MRI, biomarker testing and active surveillance. These measures aim to identify potentially aggressive cancers while reducing unnecessary biopsies and treatment.
However, PSA screening is not suitable for everyone. Age, family history, overall health and life expectancy should influence individual decisions.
The key message is that early detection should be supported by careful clinical assessment. Men should understand the potential benefits and limitations of screening and discuss the most appropriate approach with their healthcare provider.
